￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Oncology

Larotrectinib brings new options to patients with NRTK-positive lung cancer

2025-10-19 11:44:20

Check Details
How long can patients with liver cancer live after regorafenib treatment?

2025-10-19 11:44:20

Check Details
Larotinib is a broad-spectrum anti-tumor drug applied to the NTRK target_ Kanghule

2025-10-19 11:44:20

Check Details
How much does a box of NTRK gene fusion targeting drug larotrectinib cost? Where can I buy it?

2025-10-19 11:44:20

Check Details
How should larotrectinib, which is different from traditional targeted drugs targeting the primary site, be taken?

2025-10-19 11:44:20

Check Details
Larotrectinib can be used to treat patients with NTRK gene fusions_Canghule

2025-10-19 11:44:20

Check Details
Activity and safety of crizotinib (Xalkori) in ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Efficacy of Lorlatinib

2025-10-19 11:44:20

Check Details
Learn more about the new anti-cancer drug Sotorasib about non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Mobocertinib receives FDA priority review status for the treatment of exon 20 mutated non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Do you know the main diagnostic methods for lung cancer?

2025-10-19 11:44:20

Check Details
The effect of Lorlatinib in the first-line treatment of non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Category
相关知识